February 20, 2024 News by Margarida Maia, PhD Nabiximols, cannabis-based spray, eases spasticity in real-world use Nabiximols, a cannabis-based oral spray sold as Sativex, was reported to considerably ease spasticity ā unusual muscle tightness or stiffness ā in about two-thirds of the multiple sclerosis (MS) patients using it for three months in a real-world study in Germany. For most patients, the treatment also…
October 23, 2023 News by Patricia Inacio, PhD Sativex reimbursed in Ireland for eligible MS patients with spasticity Nabiximols, the cannabis-based oral spray sold as Sativex, is available for reimbursement as an add-on therapy for moderate to severe spasticity in adults with multiple sclerosis (MS) in Ireland who failed to respond as intended to other spasticity medications. Marked by muscle stiffness and involuntary spasms or twitches,…
May 23, 2023 News by Marisa Wexler, MS Cannabis oral spray nabiximols found to ease spasticity in MS Treatment with the cannabis oral spray nabiximols helped to relieve spasticity ā increased muscle stiffness and spasms common in people with multiple sclerosis (MS) ā among participants in two MS clinical trials, according to the results of a new analysis. “In this analysis, nabiximols was shown to significantly…
April 3, 2023 News by Lindsey Shapiro, PhD Sativex eases MS spasticity and related symptoms in real-life study Real-world use of nabiximols, an oral spray cannabinoid treatment, was associated with a self-reported easing of spasticity and related symptoms for people with multiple sclerosis (MS), according to a recent study in Austria. Most patients (87.5%) said they were at least partly satisfied with the therapy ā available…
October 21, 2022 News by Margarida Maia, PhD 4 Weeks of Nabiximols Found to Ease Spasticity in MS Pilot Study Four weeks of treatment with nabiximolsĀ ā an oral spray containing compounds found in the cannabis plant ā significantly reduced spasticity and generally improved arm and hand function in multiple sclerosis (MS) patients with moderate-to-severe spasticity, according to a small pilot study in Italy. Notably, after nabiximols, patients showed…
July 8, 2022 Columns by Ed Tobias Trial Results a Setback for US Approval of Nabiximols for MS Spasticity This news seems disappointing: A Phase 3 clinical trial of nabiximols ā which is available under the brand name Sativex in several countries, including Canada and most of Europe ā has failed to meet its primary goal of reducing leg spasticity in people with multiple sclerosis (MS). Nabiximols…
July 5, 2022 News by Lindsey Shapiro, PhD Assistive Device Makes It Easier to Self-administer Nabiximols: Study An assistive device made it significantly easier and more comfortable for multiple sclerosis (MS) patients with arm and hand mobility problems to self-administer nabiximols ā an oral spray containing compounds found in the cannabis plant ā a study found. Trained nurses involved in the study agreed with its…
June 29, 2022 News by Lindsey Shapiro, PhD Nabiximols Fails to Meet Trial Goal of Easing Leg Spasticity The Phase 3 RELEASE MSS1 clinical trial testing nabiximols oral spray failed to meet its primary goal of easing leg spasticity in patients with multiple sclerosis (MS), according to Jazz Pharmaceuticals, the company currently developing the nabiximols clinical program. Enrolling 68 MS patients,…
March 28, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: aHSCT, Cannabis, Smell Test, Telemedicine Stem Cell Transplant Gaining Ground as MS Therapy Option This comprehensive look at stem cell transplants by Multiple Sclerosis News Today writer Hawken Miller is one of the best overviews of the possible benefits and dangers and the current status of autologous hematopoietic stem cell transplantation (aHSCT) that…
October 15, 2021 News by Marisa Wexler, MS #ECTRIMS2021 ā Sativex Eases MS Patients’ Spasticity, Spasms in Trials Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ hereĀ to see the latest stories from the conference. Sativex…
August 23, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Ocrevus, Probiotics, Floodlight App, Sativex in UK Trial Will Test Ocrevus on Arm, Hand Function in PPMS A lot of the focus in MS treatment and clinical trials is placed on walking ability. It seems to me that only recently has attention been paid to above-the-waist disabilities. I know that many people with MS have problems…
August 20, 2021 News by Margarida Maia, PhD Barriers Limit Sativex Access for Patients With Spasticity in UK Sativex (nabiximols), a cannabis-based oral spray approved in the U.K. to ease spasticity ā or muscle stiffness and spasms ā in adults with multiple sclerosis (MS), remains unavailable to many patients there, according to a report by the MS Society UK. Sativex is the only licensed…
August 16, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Mavenclad, Sativex, Mistreatment, Patient Survey Trial Will Test Mavenclad for Advanced Progressive MS I often think that researchers have forgotten about people whose MS has progressed to an advanced stage. But MS patients who have moved into a wheelchair deserve treatment with a disease-modifying therapy as much as those who are just beginning their…
August 10, 2021 News by Patricia Inacio, PhD Third Phase 3 Trial of Sativex, Cannabis Extract for MS Spasticity, Planned Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial ofĀ Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5…
July 8, 2021 News by Patricia Inacio, PhD Sativex Eased MS Spasticity as an Add-on Therapy Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticityĀ in adultĀ multiple sclerosisĀ (MS) patients who failed to respond to other anti-spastic treatments,Ā a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity ā muscle stiffness or…
January 13, 2021 News by Joana Carvalho, PhD GW Pharma Plans More Clinical Trials for Sativex GW Pharmaceuticals is planning to continue recruiting patientsĀ into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is…
November 9, 2020 Columns by Ed Tobias MS News That Caught My Eye Last Week: Age and DMTs, Tysabri or Gilenya, Sativex Trial, Ocrevus and Mayzent Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US This is a major step toward making a clinically tested, cannabis-based medication available in the U.S. I’ve always thought that medications containing a THC/CBD combination are useful to lessen some MS symptoms, but the lack…
November 5, 2020 News by Joana Carvalho, PhD Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of SativexĀ (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity ā muscle stiffness or spasms ā associated with multiple sclerosis (MS). Sativex, by…